Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 7, 2014, Pages 475-481

  Xu, Rui Xia ^a   Guo, Yuan Lin ^a   Li, Xiao Lin ^a   Li, Sha ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Atherosclerosis; Atorvastatin; High density lipoprotein subfraction; Low density lipoprotein particle size; Low density lipoprotein subfraction

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; UREA NITROGEN BLOOD LEVEL; BLOOD; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION; HYPERLIPIDEMIAS; MIDDLE AGED;

ADULT; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES;

EID: 84903883966     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12243     Document Type: Article

References (26)

1. Martin SS, Blaha MJ, Blankstein R et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: Implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation 2014; 129: 77-86.
2. Li JJ, Yang P, Liu J et al. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. Clin. Chim. Acta 2012; 413: 139-42.
3. Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A Working Group report and update. J. Am. Coll. Cardiol. 2004; 43: 717-24.
4. Vergeer M, Holleboom AG, Kastelein JJ et al. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J. Lipid Res. 2010; 51: 2058-73.
5. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 2008; 51: 2199-211.
6. Mackey RH, Greenland P, Goff DC Jr et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 2012; 60: 508-16.
7. Rosenson RS, Brewer HB, Chapman JM et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 2011; 57: 392-410.
8. Rizzo JA1, Mallow PJ, Waters HC et al. Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: a cost-effectiveness analysis. J. Clin. Lipidol. 2013; 7: 642-52.
9. Guo YL, Liu J, Li JJ et al. A multi-center survey of achieving recommended lipid goals in Chinese patients with coronary artery disease in real world cardiovascular practice. Int. J. Cardiol. 2011; 153: 211-12.
10. Kostapanos MS, Milionis HJ, Filippatos TD et al. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J. Cardiovasc. Pharmacol. Ther. 2009; 14: 5-13.
11. Agouridis AP, Kostapanos MS, Tsimihodimos V et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int. J. Clin. Pract. 2012; 66: 843-53.
12. Geiss HC, Otto C, Schwandt P et al. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism 2001; 50: 983-8.
13. Toth PP, Thakker KM, Jiang P et al. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vasc. Health Risk Manag. 2012; 8: 39-44.
14. Frost RJ, Otto C, Geiss HC et al. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. 2001; 87: 44-8.
15. Winkler K, Weltzien P, Friedrich I et al. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp. Clin. Endocrinol. Diabetes 2004; 112: 241-7.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002; 106: 3143-421.
17. Superko HR, Gadesam RR. Is it LDL particle size or number that correlates with risk for cardiovascular disease? Curr. Atheroscler. Rep. 2008; 10: 377-85.
18. Irving BA, Nair KS, Srinivasan M. Effects of insulin sensitivity, body composition, and fitness on lipoprotein particle sizes and concentrations determined by nuclear magnetic resonance. J. Clin. Endocrinol. Metab. 2011; 96: E713-18.
19. Harchaoui KE, van der Steeg WA, Stroes ES et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol. 2007; 49: 547-53.
20. Kappelle PJ, Dallinga-Thie GM, Dullaart RP et al. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochim. Biophys. Acta 2010; 1801: 89-94.
21. Soedamah-Muthu SS, Colhoun HM, Thomason MJ et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003; 167: 243-55.
22. Ikewaki K, Terao Y, Ozasa H et al. Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia. J. Atheroscler. Thromb. 2009; 16: 51-6.
23. Chung M, Lichtenstein AH, Ip S et al. Comparability of methods for LDL subfraction determination: A systematic review. Atherosclerosis 2009; 205: 342-8.
24. Goliasch G, Oravec S, Blessberger H et al. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (≤40 years of age). Eur. J. Clin. Invest. 2012; 42: 631-6.
25. Christogiannis LG, Kostapanos MS, Tellis CC et al. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J. Hum. Hypertens. 2013; 27: 44-50.
26. Banuls C, Bellod L, Jover A et al. Comparability of two different polyacrylamide gel electrophoresis methods for the classification of LDL pattern type. Clin. Chim. Acta 2012; 413: 251-7.